Database / Research Profiles / PT-141 / Bremelanotide
Compare
RESEARCH PROFILE

PT-141 / BREMELANOTIDE

Melanocortin receptor agonist
Sexual healthApproved human therapeutic (specific indication)
EVIDENCE SNAPSHOTAPPROVED HUMAN THERAPEUTIC (SPECIFIC INDICATION)

This is an example where the molecule has an approved medical indication; ApeX should clearly separate approved labeling from off-label or research claims.

Research-first: This profile summarizes published evidence and regulatory context. It is educational reference material, not a diagnosis, treatment recommendation, or personalized dosing protocol.

01 — What is it?

Bremelanotide is a melanocortin receptor agonist. In the U.S., Vyleesi is FDA-approved for acquired, generalized HSDD in premenopausal women and is not indicated to enhance sexual performance.

02 — Research category

Sexual health. Evidence strength is based on the availability and quality of human clinical data, not on popularity in the research-peptide market.

03 — Evidence map

Human evidence: YESPreclinical evidence: SUPPLEMENTALPersonal dosing protocol: NOT PROVIDED

This is an example where the molecule has an approved medical indication; ApeX should clearly separate approved labeling from off-label or research claims.

04 — Mechanism / biology

Bremelanotide is a melanocortin receptor agonist. In the U.S., Vyleesi is FDA-approved for acquired, generalized HSDD in premenopausal women and is not indicated to enhance sexual performance.

05 — Safety & limitations

Safety depends on the exact molecule, formulation, route, dose, indication and study population. Research-market products may differ in identity, purity, sterility or stability from materials used in published trials. Absence of reported adverse events in a small study does not establish long-term safety.

06 — Regulatory context

Regulatory status varies by compound and jurisdiction. Where an approved product exists, its approval applies only to specified formulations and indications. Investigational or research-market status should not be presented as equivalent to approval.